First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G.
Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21.
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up().
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.
Ann Oncol. 2022 Feb;33(2):129-142. doi: 10.1016/j.annonc.2021.11.005. Epub 2021 Nov 30.
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, Husain AN, Kadota K, Khoor A, Nicholson AG, Roggli V, Schmitt F, Tsao MS, Travis WD.
J Thorac Oncol. 2022 May;17(5):608-622. doi: 10.1016/j.jtho.2021.12.014. Epub 2022 Jan 10.
Non-incisional pleurectomy/decortication for malignant mesothelioma after cardiac surgery.
Miura K, Shimizu K, Hasegawa S, Koike S, Matsuoka S, Takeda T, Eguchi T, Hamanaka K, Takizawa M.
Thorac Cancer. 2022 Jan;13(1):126-128. doi: 10.1111/1759-7714.14231. Epub 2021 Nov 20.
Pericardial Mesothelioma, a Disease for Brave Hearts.
Grosso F, Cerbone L, Pasello G.
J Thorac Oncol. 2022 Dec;17(12):1333-1334. doi: 10.1016/j.jtho.2022.09.224.
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.
Chiaro J, Antignani G, Feola S, Feodoroff M, Martins B, Cojoc H, Russo S, Fusciello M, Hamdan F, Ferrari V, Ciampi D, Ilonen I, Räsänen J, Mäyränpää M, Partanen J, Koskela S, Honkanen J, Halonen J, Kuryk L, Rescigno M, Grönholm M, Branca RM, Lehtiö J, Cerullo V.
Nat Commun. 2023 Nov 3;14(1):7056. doi: 10.1038/s41467-023-42668-7.
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells.
Chrisochoidou Y, Roy R, Farahmand P, Gonzalez G, Doig J, Krasny L, Rimmer EF, Willis AE, MacFarlane M, Huang PH, Carragher NO, Munro AF, Murphy DJ, Veselkov K, Seckl MJ, Moffatt MF, Cookson WOC, Pardo OE.
Cell Death Dis. 2023 Nov 8;14(11):725. doi: 10.1038/s41419-023-06240-x.
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.
Lim E, Waller D, Lau K, Steele J, Pope A, Ali C, Bilancia R, Keni M, Popat S, O'Brien M, Tokaca N, Maskell N, Stadon L, Fennell D, Nelson L, Edwards J, Tenconi S, Socci L, Rintoul RC, Wood K, Stone A, Muthukumar D, Ingle C, Taylor P, Cove-Smith L, Califano R, Summers Y, Tasigiannopoulos Z, Bille A, Shah R, Fuller E, Macnair A, Shamash J, Mansy T, Milton R, Koh P, Ionescu AA, Treece S, Roy A, Middleton G, Kirk A, Harris RA, Ashton K, Warnes B, Bridgeman E, Joyce K, Mills N, Elliott D, Farrar N, Stokes E, Hughes V, Nicholson AG, Rogers CA; MARS 2 Investigators.
Lancet Respir Med. 2024 Jun;12(6):457-466. doi: 10.1016/S2213-2600(24)00119-X. Epub 2024 May 10.
Primary pericardial mesothelioma.
Eren NT, Akar AR.
Curr Treat Options Oncol. 2002 Oct;3(5):369-73. doi: 10.1007/s11864-002-0002-7.
Cardiac mesothelioma.
Krishnarathnam K, Subramanian S.
J Assoc Physicians India. 1991 Jun;39(6):499-500.
